MedTrace Logo

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

NCT02865811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-09-13

Study results available
· View outcomes & findings →

Summary

This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy.

The following interventions will be used in this study:

* Pegylated liposomal doxorubicin (PLD)
* Pembrolizumab

Conditions

Interventions

DRUG

Pembrolizumab

Please see "Arms" for description.

DRUG

Pegylated Liposomal Doxorubicin (PLD)

Please see "Arms" for description.

Sponsors & Collaborators

Principal Investigators

  • Ursula Matulonis, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-15
Primary Completion
2020-08-31
Completion
2022-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865811 on ClinicalTrials.gov